SCHEMBL6153269

SCHEMBL6153269

Cc1ccc(CN2C(=O)C3=C(c4cccc5c4ccc4ccccc45)N(Cc4ccc(C)cc4)C(=O)C3=C2c2cccc3c2ccc2ccccc23)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.45
CLTC Q00610 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
P2RX4 Q99571 1/20 0.41
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
MDH2 P40926 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
POLB P06746 2/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
PABPC1 P11940 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2457896 0.94 GSK3B (0.47) GSK3BCLTCNPSR1P2RX4CA12
SCHEMBL10086968 0.87 P2RX4 (0.43) GSK3BCLTCP2RX4CA12CA9
SCHEMBL2457350 0.83 RGS4 (0.41) GSK3BCLTCP2RX4CA12CA9
SCHEMBL2457775 0.83 NPSR1 (0.56) GSK3BCLTCNPSR1KDM4ESMN1; SMN2
SCHEMBL6153208 0.82 RGS4 (0.47) P2RX4CA12CA9MDH2ADRA1D
SCHEMBL2457538 0.80 NPSR1 (0.42) GSK3BNPSR1CA12CA9KDM4E
SCHEMBL6152233 0.74 HPRT1 (0.45) GSK3BKDM4ESMN1; SMN2TDP1POLB
SCHEMBL2457833 0.74 CYP1B1 (0.51) NPSR1KDM4ESMN1; SMN2POLBMAPT
SCHEMBL8737445 0.73 CASP3 (0.65) NPSR1CA12CA9ADRA1DADRA1A
SCHEMBL29820192 0.73 CASP3 (0.65) NPSR1CA12CA9ADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1253151-B1 Pyrromethene metal complex and light emitting device composition and light emitting devices using the same TORAY INDUSTRIES (JP) 2005-01-12 EP disclosed
US-6805978-B2 COMPLEX CONTAINING DIKETOPYRROLO(3,4-C)PYRROLE COMPOUND TORAY INDUSTRIES, INC. (JP) 2004-10-19 US disclosed
US-20030082406-A1 Complex containing diketopyrrolo(3,4-c)pyrrole compound TORAY INDUSTRIES, INC. (JP) 2003-05-01 US disclosed
EP-1253151-A1 Pyrromethene metal complex and light emitting device composition and light emitting devices using the same TORAY INDUSTRIES, INC. (JP) 2002-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030082406-A1 Complex containing diketopyrrolo(3,4-c)pyrrole compound PPOX, CPNE4, TP53RK GSK3B 3956/4885CLTC 694/4885NPSR1 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.